Hypoglycemia: Clinical Trials

49 trials for Hypoglycemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

34 completed, 6 unknown, 4 terminated, 2 withdrawn. 49 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 449Completed 34, Unknown 6, Terminated 4, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1

Follow Hypoglycemia: new trials by email Literature Review of Hypoglycemia trials Research Report on Hypoglycemia

Trials (filtered) newest first · largest first

All 49 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)
Glucagon for Injection (Fresenius Kabi USA), [6,6-2H2] glucose, [13C9, 15N1]-glucagon - Hypoglycemia, Hypoglycemia, Reactive
Phase 4RecruitingJoslin Diabetes Center402026-01-272026-09-14
Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Dapagliflozin (DAPA), Pioglitazone 45 mg, Placebo - Type 1 Diabetes
Phase 4Not yet recruitingDasman Diabetes Institute602025-09-152025-08-29
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Metformin, Dulaglutide, Semaglutide 1.0 mg - Diabetes Mellitus Type 2
Phase 4CompletedFundación para la Investigación del Hospital Clínico de Valencia922025-05-262026-09-04
Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia
Glucagon for Injection (Fresenius Kabi USA) - Hypoglycemia, Hypoglycemia, Reactive
Phase 4Active not recruitingJoslin Diabetes Center282024-11-262026-02-06
Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass
Empagliflozin 25 MG, Placebo - Dumping Syndrome, Hypoglycemia, Reactive
Phase 4CompletedInsel Gruppe AG, University Hospital Bern222021-12-012023-03-14
Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes
Glucagon, Closed-loop system - Type 1 Diabetes, Hypoglycemia
Phase 4CompletedSteno Diabetes Center Copenhagen132019-07-162022-08-18
Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)
Naloxone, Diazoxide, Placebo (for Naloxone) - Diabetes Mellitus, Type 1, Hypoglycemia
Phase 4TerminatedAlbert Einstein College of Medicine42019-01-082025-09-11
Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Pasireotide 0.3 MG/ML, Meal tolerance test (MTT) - Hypoglycemia, Reactive
Phase 4UnknownZealand University Hospital52018-06-012018-07-05
Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia
Ciprofloxacin 400 MG/200 ML Intravenous Solution, Levofloxacin 750 MG - QTc Prolongation, Hyperglycemia, Hypoglycemia
Phase 4CompletedBeni-Suef University2002018-06-012020-07-02
Ramadan Fasting in Patients With Corticotrope Deficiency Treated Either by Hydrocortisone or by Prednisolone
Hydrocortisone, Prednisolone - Corticotropin Deficiency, Fasting
Phase 4CompletedUniversity Tunis El Manar532018-05-172019-04-29
Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
NPH Insulin, glargine, Insulin Aspart - Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Phase 4TerminatedNorthwestern University32018-03-272020-09-11
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study
Technosphere insulin - Diabetes Mellitus, Type 1
Phase 4CompletedUniversity of Colorado, Denver602017-09-302022-02-22
Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan
Metformin and Glimepiride (Low Dosage), Metformin and Vildagliptin (Low Dosage), Metformin and Insulin Glargine U100 (Low Dosage) - Diabetes Mellitus, Type 2
Phase 4CompletedUniversity of Jordan6872017-02-142020-02-11
The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes
Alcohol, Placebo - Hypoglycemia, Diabetes Mellitus, Type 1
Phase 4CompletedHvidovre University Hospital122016-08-012017-07-24
Pasireotide Treatment for Neuroendocrine Tumor
Pasireotide, Diazoxide - Gastro-enteropancreatic Neuroendocrine Tumor
Phase 4WithdrawnUniversity of Maryland, Baltimore2016-04-012022-03-04
Comparison of 2 Hyperglycemia-correction Scales in Hospitalized Patients
Insulin, insulin - Diabete Type 2, Hyperglycemia
Phase 4CompletedHospital Universitario Clinica San Rafael1162016-01-012023-03-03
Treatment of Hypoglycemia Following Gastric Bypass Surgery
Glucobay (acarbose), Januvia (sitagliptin), Verapamil HEXAL (verapamil) - Hypoglycemia, Obesity
Phase 4CompletedZealand University Hospital112015-10-012018-03-07
Glucagon Efficiency After High and Low Carbohydrate Diet
High carbohydrate intake, Low carbohydrate intake - Type 1 Diabetes, Hypoglycemia
Phase 4CompletedHvidovre University Hospital102015-10-012016-08-16
Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes
Insulin glargine, Insulin aspart, Supplemental insulin aspart - Diabetes Mellitus, Type 2
Phase 4CompletedEmory University2262015-10-012023-09-28
Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial
Insulin, Aspart - Gestational Diabetes, Hypoglycemia, Neonatal
Phase 4UnknownTampere University Hospital502015-09-012019-10-23

Showing 20 of 49. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 1 (16)  ·  Diabetes Mellitus (12)  ·  Diabetes Mellitus, Type 2 (11)  ·  Hyperglycemia (11)  ·  Insulin Resistance (5)  ·  Fasting (3)  ·  Adrenocorticotropic hormone deficiency (1)  ·  Autoimmune Diseases (1)  ·  Brain Injuries, Traumatic (1)  ·  Congenital Hyperinsulinism (1)  ·  Critical Illness (1)  ·  Diabetes, Gestational (1)  ·  Diabetic Ketoacidosis (1)  ·  Dumping Syndrome (1)

Broader conditions

Nutritional and Metabolic Diseases (49)  ·  Glucose Metabolism Disorders (48)  ·  Metabolic Diseases (48)  ·  Endocrine System Diseases (31)  ·  Diabetes Mellitus (20)  ·  Immune System Diseases (16)  ·  Autoimmune Diseases (15)  ·  Behavior (6)  ·  Hyperinsulinism (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Feeding Behavior (4)  ·  Pathologic Processes (4)  ·  Acid-Base Imbalance (2)  ·  Acidosis (2)  ·  Body Weight (2)

Interventions

Insulin Glargine (8)  ·  Insulin Aspart (6)  ·  Vildagliptin (6)  ·  Insulin (4)  ·  Metformin (4)  ·  Sitagliptin Phosphate (4)  ·  Diazoxide (3)  ·  Glucagon (3)  ·  Insulin Detemir (3)  ·  pasireotide (3)  ·  Glucose (2)  ·  Injections (2)  ·  Isophane Insulin, Human (2)  ·  Liraglutide (2)  ·  Pioglitazone (2)

Sponsors

Joslin Diabetes Center (3)  ·  Emory University (2)  ·  Hvidovre University Hospital (2)  ·  Lund University (2)  ·  Northwestern University (2)  ·  Novartis Pharmaceuticals (2)  ·  Steno Diabetes Center Copenhagen (2)  ·  Tampere University Hospital (2)  ·  Zealand University Hospital (2)  ·  Albert Einstein College of Medicine (1)  ·  Bassett Healthcare (1)  ·  Baylor College of Medicine (1)  ·  Beni-Suef University (1)  ·  Brigham and Women's Hospital (1)  ·  Buckinghamshire Healthcare NHS Trust (1)

Countries

United States (11)  ·  Denmark (9)  ·  United Kingdom (6)  ·  Egypt (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Jordan (2)  ·  Kuwait (2)  ·  Saudi Arabia (2)  ·  Spain (2)  ·  Sweden (2)  ·  Tunisia (2)  ·  Turkey (Türkiye) (2)  ·  Australia (1)

Top investigators

Ahmed A Elberry, professor (1)  ·  Ajenthen G Ranjan, MD, PhD (1)  ·  Ajenthen Ranjan, MD (1)  ·  Ananda Basu, MD (1)  ·  Andreas Fritsche, MD (1)  ·  Ayman A. Zayed, MD (1)  ·  Caroline C Gormsen, M.D. (1)  ·  Colin McArthur, MBBS (1)  ·  Dalit Modan, M.D. (1)  ·  Dario Giugliano, MD,PhD (1)  ·  Deborah Cook, MBBS (1)

Results publications

PMID 37526194, PMID 11889147, PMID 15793249, PMID 17513708, PMID 19158048, PMID 19190104, PMID 19318384, PMID 19719706, PMID 19885233, PMID 21228246, PMID 21387555, PMID 21697252, PMID 22223765, PMID 22727048, PMID 22784834, PMID 22855332, PMID 22992074, PMID 22996038, PMID 23435159, PMID 24794703, PMID 24920915, PMID 25838513, PMID 26474657, PMID 26537183, PMID 26656289, PMID 27068361, PMID 27326862, PMID 27797928, PMID 27995731, PMID 30207748, PMID 30679302, PMID 31337371, PMID 31907828, PMID 34305809, PMID 35467938, PMID 35675498, PMID 36123073, PMID 37093196, PMID 37435938, PMID 37671755, PMID 37853343, PMID 8422838

NIH funding

R01DK137518 (2), 2005 (1), 2019 (1), 2025 (1), K24HL103845 (1), R01DK079974 (1), R01HL109634 (1), UL1TR001102 (1)